Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus Type 2

In brief

This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.

Key facts

Study ID

NCT01516476

Run by

Hoffmann-La Roche

People needed

2

Starts

2011-11-01

Expected to finish

2012-01-01

Last updated by the study team

2016-11-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients >/= 18 and </=70 years of age
• Diagnosis of diabetes mellitus, type 2 for at least 3 months
• Treated with a stable dose of metformin
• Hemoglobin A1c >/=7.0% and </=10.5% at screening
• Fasting plasma glucose </=240 mg/dL at screening
• Body mass index >/=27 kg/m2 and </=42 kg/m2 at screening
• Willing and able to maintain existing diet and exercise habits throughout the study
• C-peptide >1.5 ng/mL at screening

You may not qualify if…

• History of significant liver or kidney disease
• History of uncontrolled hypertension
• History of significant cardiovascular disease
• History of significant diabetic complications
• History of significant gastrointestinal conditions
• History of weight loss surgery or procedures involving the gastrointestinal tract
• History of chronic or acute pancreatitis

Where it is running

• Study site — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.